Literature DB >> 25185644

An update on the medical treatment of Graves' hyperthyroidism.

Michele Marinò1, Francesco Latrofa, Francesca Menconi, Luca Chiovato, Paolo Vitti.   

Abstract

Medical treatment of Graves' hyperthyroidism is based on the use of thionamides; namely, methimazole and propylthiouracil. In the past, methimazole was preferred by European endocrinologists, whereas propylthiouracil was the first choice for the majority of their North American colleagues. However, because of the recent definition of a better side-effect profile, methimazole is nowadays the first choice world while. Although thionamides are quite effective for the short-term control of Graves' hyperthyroidism, a relatively high proportion of patients relapses after thionamide withdrawal. Other possible medical treatments, include iodine and compounds containing iodine, perchlorate, lithium (as an adjuvant in patients undergoing radioiodine therapy), β-adrenergic antagonists, glucocorticoids, and some new molecules still under investigation. Management of Graves' hyperthyroidism using thionamides as well as the other available medical treatments is here reviewed in detail, with a special mention of situations such as pregnancy and lactation, as well as neonatal and fetal thyrotoxicosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25185644     DOI: 10.1007/s40618-014-0136-z

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  56 in total

1.  Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment.

Authors:  P Vitti; T Rago; L Chiovato; S Pallini; F Santini; E Fiore; R Rocchi; E Martino; A Pinchera
Journal:  Thyroid       Date:  1997-06       Impact factor: 6.568

2.  Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists.

Authors:  Rebecca S Bahn Chair; Henry B Burch; David S Cooper; Jeffrey R Garber; M Carol Greenlee; Irwin Klein; Peter Laurberg; I Ross McDougall; Victor M Montori; Scott A Rivkees; Douglas S Ross; Julie Ann Sosa; Marius N Stan
Journal:  Thyroid       Date:  2011-04-21       Impact factor: 6.568

3.  The Role of Propylthiouracil in the Management of Graves' Disease in Adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration.

Authors:  Rebecca S Bahn; Henry S Burch; David S Cooper; Jeffrey R Garber; Carol M Greenlee; Irwin L Klein; Peter Laurberg; I Ross McDougall; Scott A Rivkees; Douglas Ross; Julie Ann Sosa; Marius N Stan
Journal:  Thyroid       Date:  2009-07       Impact factor: 6.568

4.  B cell-targeted therapy with anti-CD20 monoclonal antibody in a mouse model of Graves' hyperthyroidism.

Authors:  I Ueki; N Abiru; M Kobayashi; M Nakahara; T Ichikawa; K Eguchi; Y Nagayama
Journal:  Clin Exp Immunol       Date:  2011-01-14       Impact factor: 4.330

5.  Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in treated Graves' disease patients.

Authors:  H Tamai; I Hayaki; K Kawai; G Komaki; S Matsubayashi; K Kuma; L F Kumagai; S Nagataki
Journal:  J Clin Endocrinol Metab       Date:  1995-05       Impact factor: 5.958

6.  Serum iodothyronines in the human fetus and the newborn: evidence for an important role of placenta in fetal thyroid hormone homeostasis.

Authors:  F Santini; L Chiovato; P Ghirri; P Lapi; C Mammoli; L Montanelli; G Scartabelli; G Ceccarini; L Coccoli; I J Chopra; A Boldrini; A Pinchera
Journal:  J Clin Endocrinol Metab       Date:  1999-02       Impact factor: 5.958

7.  Inhibitory effect of various radiographic contrast agents on secretion of thyroxine by the dog thyroid and on peripheral and thyroidal deiodination of thyroxine to tri-iodothyronine.

Authors:  P Laurberg; N Boye
Journal:  J Endocrinol       Date:  1987-03       Impact factor: 4.286

Review 8.  Chronic idiopathic urticaria and Graves' disease.

Authors:  R M Ruggeri; S Imbesi; S Saitta; A Campennì; S Cannavò; F Trimarchi; S Gangemi
Journal:  J Endocrinol Invest       Date:  2013-04-18       Impact factor: 4.256

9.  Pregnancy-associated changes in the thyroid-stimulating antibody of Graves' disease and the relationship to neonatal hyperthyroidism.

Authors:  M Zakarija; J M McKenzie
Journal:  J Clin Endocrinol Metab       Date:  1983-11       Impact factor: 5.958

10.  Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease.

Authors:  U Feldt-Rasmussen; H Schleusener; P Carayon
Journal:  J Clin Endocrinol Metab       Date:  1994-01       Impact factor: 5.958

View more
  18 in total

1.  Safety of long-term antithyroid drug treatment? A systematic review.

Authors:  F Azizi; R Malboosbaf
Journal:  J Endocrinol Invest       Date:  2019-05-27       Impact factor: 4.256

Review 2.  Relapse prediction in Graves´ disease: Towards mathematical modeling of clinical, immune and genetic markers.

Authors:  Christoph Langenstein; Diana Schork; Klaus Badenhoop; Eva Herrmann
Journal:  Rev Endocr Metab Disord       Date:  2016-12       Impact factor: 6.514

3.  Pregnancy outcome in women treated with methimazole or propylthiouracil during pregnancy.

Authors:  E Gianetti; L Russo; F Orlandi; L Chiovato; M Giusti; S Benvenga; M Moleti; F Vermiglio; P E Macchia; M Vitale; C Regalbuto; M Centanni; E Martino; P Vitti; M Tonacchera
Journal:  J Endocrinol Invest       Date:  2015-04-04       Impact factor: 4.256

4.  Long-term outcome of Graves' orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy.

Authors:  E Sisti; F Menconi; M Leo; M A Profilo; T Mautone; B Mazzi; R Rocchi; F Latrofa; M Nardi; P Vitti; C Marcocci; M Marinò
Journal:  J Endocrinol Invest       Date:  2015-01-18       Impact factor: 4.256

Review 5.  Role of genetic and non-genetic factors in the etiology of Graves' disease.

Authors:  M Marinò; F Latrofa; F Menconi; L Chiovato; P Vitti
Journal:  J Endocrinol Invest       Date:  2014-11-25       Impact factor: 4.256

Review 6.  [Autoimmune diseases of the thyroid gland].

Authors:  S Allelein; J Feldkamp; M Schott
Journal:  Internist (Berl)       Date:  2017-01       Impact factor: 0.743

Review 7.  Total thyroid ablation in Graves' orbitopathy.

Authors:  F Menconi; M Leo; P Vitti; C Marcocci; M Marinò
Journal:  J Endocrinol Invest       Date:  2015-03-05       Impact factor: 4.256

8.  Graves' orbitopathy, idiopathic orbital inflammatory pseudotumor and Epstein-Barr virus infection: a serological and molecular study.

Authors:  M Leo; F Maggi; G R Dottore; G Casini; P Mazzetti; M Pistello; S Sellari-Franceschini; M Nardi; P Vitti; C Marcocci; M Marinò
Journal:  J Endocrinol Invest       Date:  2016-12-16       Impact factor: 4.256

9.  Oxidative Stress in Graves Disease and Graves Orbitopathy.

Authors:  Giulia Lanzolla; Claudio Marcocci; Michele Marinò
Journal:  Eur Thyroid J       Date:  2020-11-20

10.  Low regulatory T cell and high IL-17 mRNA expression in a mouse Graves' disease model.

Authors:  Q Yuan; Y Zhao; X Zhu; X Liu
Journal:  J Endocrinol Invest       Date:  2016-11-07       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.